Floatz Rating
CCC48/100
Confidence
Indicative
Sponsor
GeoVax, Inc.
Modality
vaccine
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT04977024CT.gov SARS-CoV-2 Vaccine (GEO-CM04S1) Versus mRNA SARS-COV-2 Vaccine in Patients With Blood Cancer | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Leukemia
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1 (this asset) | GeoVax, Inc. | P2 | CCC · 48 |
| Vincristine Sulfate | Inhye Ahn | P3 | BB |
| Cyclophosphamide | National Cancer Institute (NCI) | P4 | BB |
| Idarubicin | Affiliated Hospital of Nantong University | P3 | BB |
| Mercaptopurine Anhydrous | Dana-Farber Cancer Institute | P3 | BB |
| Thioguanine Anhydrous | Incyte Corporation | P3 | BB |
| Nivestim | Hospital General de Mexico | P4 | BB |
| Daunomycin | Richard Stone, MD | P3 | BB |
| Pegaspargase | Dana-Farber Cancer Institute | P3 | BB |
+42 more in the Leukemia cohort
Other indications for Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| COVID-19 | — | P2 | CCC · 53 |
| Hematopoietic And Lymphoid System Neoplasm | — | P2 | CCC · 53 |
| Plasma Cell Myeloma | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Synthetic Mva-Based Sars-Cov-2 Vaccine Geo-Cm04S1 in Leukemia. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/synthetic-mva-based-sars-cov-2-vaccine-geo-cm04s1-leukemia
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →